This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Brian's Big Idea on Biotech
by Brian Bolan
A look at drugs for drug addiction and the biotech space.
Take the Zacks Approach to Beat the Market: Shopify, Oracle, Uber in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Avis Budget Group and Vulcan Materials have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Avis Budget Group and Vulcan Materials have been highlighted as Zacks Bull and Bear of the Day.
3 Medical Stocks Creating Wealth Despite Macro Challenges
by Indrajit Bandyopadhyay
Here we discuss three stocks - LNTH, OMER and HYPR - that have been creating wealth for their investors in 2023 even though several competitors faltered amid macro challenges. Will the trend continue?
Wall Street Analysts See a 126% Upside in Omeros (OMER): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 126.2% upside potential for Omeros (OMER). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Earnings Season Could Be Great for Omeros (OMER)
by Zacks Equity Research
Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Do Options Traders Know Something About Omeros (OMER) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Omeros (OMER) stock based on the movements in the options market lately.
Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of 42.22% and 2.39%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 192% Upside in Omeros (OMER): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 192% in Omeros (OMER). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down 59.6% in 4 Weeks, Here's Why Omeros (OMER) Looks Ripe for a Turnaround
by Zacks Equity Research
Omeros (OMER) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Omeros (OMER) Soars 9.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Omeros (OMER) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Do Options Traders Know Something About Omeros (OMER) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Omeros (OMER) stock based on the movements in the options market lately.
Omeros (OMER) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of 20.00% and 11.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Omeros (OMER) Q2 Earnings Expected to Decline
by Zacks Equity Research
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor
by Zacks Equity Research
Omeros (OMER) announces initial results from a phase I study of OMS906.
Novartis (NVS) Posts Positive Data on Kidney Disease Candidate
by Zacks Equity Research
Novartis' (NVS) rare kidney disease candidate meets its primary goal in a phase II study.
Omeros (OMER) Announces Data on Narsoplimab in COVID-19 Patients
by Zacks Equity Research
Omeros (OMER) announces data on critically ill COVID-19 patients treated with lead candidate, narsoplimab.
Biotech Stock Roundup: MRNA's Vaccine Update & Pipeline Updates From REGN, BMY
by Zacks Equity Research
The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Regeneron (REGN), among others.
Omeros' (OMER) BLA for Narsoplimab Gets Extended Review
by Zacks Equity Research
The FDA extends review period for Omeros' (OMER) BLA seeking approval of narsoplimab for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy. Stock down.
Omeros (OMER) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of 1.96% and -5.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Omeros (OMER) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of 15.63% and -41.76%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omeros (OMER) in Focus: Stock Moves 8.5% Higher
by Zacks Equity Research
Omeros (OMER) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of 33.33% and 39.30%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?